By Elric Langton | 24 February 2022
Poolbeg Pharma (AIM: POLB), a clinical-stage infectious disease pharmaceutical company with a capital-light clinical model, has signed an agreement with OneThree Biotech, Inc., a biology-driven artificial intelligence (βAIβ) company, to identify new drug targets and treatments for Respiratory Syncytial Virus (βRSVβ).
Pβ¦